title: The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers.
abstract: OBJECTIVE
  The role of CYP3A5 in drug metabolism has been receiving attention because CYP3A5 may be more involved in the metabolism of CYP3A substrates in vivo than previously thought. The polymorphism of transporters, such as P-gp (P-glycoprotein) and breast cancer-related protein (BCRP), influences the metabolism of these substrates, and felodipine is a substrate of P-gp. The aim of this study was to evaluate the pharmacogenetic variability in the disposition of felodipine in healthy Chinese subjects.
  
  
  METHODS
  A single dose of 5 mg felodipine was orally administered to 45 healthy Chinese subjects. The serum concentration of felodipine was measured by using LC/MS/MS. We detected the SNPs of cytochromes P450 enzymes and transporters, which play vital roles in drug metabolism and have a high frequency of mutation in Chinese population.
  
  
  CONCLUSIONS
  The area under the plasma concentration-time curve (AUC) within the time points 0 to 72 h (AUC(0-72)) after felodipine administration was significantly higher in subjects possessing the BCRP421AA alleles than in those with the BCRP421 CC or CA genotype (P = 0·034). The subjects with CYP3A5*3/*3 (n = 27) had higher felodipine exposure than CYP3A5*1/*3 (n = 15) (P = 0·035).
  
  
  CONCLUSIONS
  This study showed that the genetic polymorphisms of CYP3A5*3 and BCRPC421A might explain the variability in the pharmacokinetics of felodipine in the Chinese population.
authors.affiliation: Department of Pharmacy, Base for Clinical Trial, Peking University First Hospital, Beijing, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Xiang
authors.affiliation: Department of Pharmacy, Base for Clinical Trial, Peking University First Hospital, Beijing, China.
authors.forename: C
authors.initials: C
authors.lastname: Li
authors.affiliation: Department of Pharmacy, Base for Clinical Trial, Peking University First Hospital, Beijing, China.
authors.forename: X
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department of Pharmacy, Base for Clinical Trial, Peking University First Hospital, Beijing, China.
authors.forename: Y M
authors.initials: YM
authors.lastname: Cui
mesh_terms: D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2 / Q000235:genetics*; D000284:Administration, Oral; D000328:Adult; D000483:Alleles; D019540:Area Under Curve; D044466:Asian People / Q000235:genetics; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D002853:Chromatography, Liquid; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D015736:Felodipine / Q000493:pharmacokinetics*; D005838:Genotype; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics*; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies; D053719:Tandem Mass Spectrometry
chemical_list: C116614:ABCG2 protein, human; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D002121:Calcium Channel Blockers; D009363:Neoplasm Proteins; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D015736:Felodipine
keywords: BCRPC421A; CYP3A5; Chinese; felodipine; pharmacokinetics